Citic Private Equity
China: Who’s investing?
Private equity investment in China remains in the doldrums yet local investors claim to see green shoots. Where, when, and how they engage with the market is likely to differ from previous cycles
China's Giant Biogene trades up after $70m Hong Kong IPO
Giant Biogene, a China-based producer of skin treatments that use bioactive ingredients, gained nearly 10% on debut following a HKD 549.4m (USD 70m) Hong Kong IPO.
CPE joins Series D for China biotech player TransThera
TransThera, a China-based drug developer, has raised $100 million in Series D funding led by CPE and China Structural Reform Fund.
Boyu stands out in weak quarter for private equity fundraising
A quickfire fundraise by Boyu Capital – which saw $6 billion collected across two pools of capital in the space of a few months – accounted for more than one-quarter of all capital committed to Asia-focused private equity managers between April and...
China hair transplant business files for Hong Kong IPO
Yonghe Medical Group, a Chinese hair healthcare specialist best known for hair transplants, is targeting a Hong Kong IPO. Its largest external shareholder is CPE, formerly CITIC Private Equity.
China-backed Oatly raises $1.4b in US IPO
Oatly, a Swedish oat-based, dairy-free beverage brand backed by a joint venture between China Resources Group and Verlinvest, raised $1.43 billion in its US IPO, facilitating partial exits for several investors.
China snack maker Weilong raises $549m, pursues HK IPO
China’s leading spicy snack food company Weilong has raised a $549 million pre-IPO round at a valuation of $9.4 billion and filed for a Hong Kong IPO.
China's ANE Logistics files for Hong Kong IPO
ANE Logistics, a Chinese road freight transportation business backed by Centurium Capital, CDH Investments, and CPE among others, has filed for a Hong Kong IPO.
China's NextData raises $135m Series D
NextData, a China-based cybersecurity services provider, has secured $135 million in Series D funding led by CPE, Matrix China Partners, Hopu Investment, Tencent Holdings, and Xiang He Capital.
China-backed Oatly pursues US IPO
Oatly, a Swedish oat-based, dairy-free beverage brand backed by a joint venture between China Resources Group and Verlinvest, has filed for a US IPO and put in place a mechanism for an additional Hong Kong listing.
CPE hits $1.8b first close on China fund
CPE has reached a first close of $1.8 billion on its fourth US dollar-denominated fund following a six-month period punctuated by three new investments and four portfolio company IPOs.
China cybersecurity player ThreatBook raises $77m
Beijing-based cybersecurity solutions provider ThreatBook has completed a RMB500 million ($77 million) Series E round led by CPE and featuring existing investor V Fund.
Deal focus: CPE backs MicroPort's medical devices agenda
CPE has backed a string of spinouts from Chinese medical device manufacturer MicroPort Medical. MicroPort CardioFlow Medtech’s Hong Kong IPO represents its first liquidity event
Brunei, CPE join Series C extension for China's Pony.ai
Chinese autonomous driving technology supplier Pony.ai has secured a Series C extension of $100 million featuring new investors Brunei Investment Agency and CPE. It takes the company’s total funding to date past $1.1 billion.
China AI specialist 4Paradigm receives $700m Series D
Boyu Capital, Primavera Capital Group, and Hopu Investments have led a $700 million Series D round for 4Paradigm, a Chinese artificial intelligence (AI) technology developer that serves enterprise customers.
China's Horizon Robotics raises $400m
Horizon Robotics, a Chinese developer of microprocessors that support artificial intelligence (AI) technologies, has raised $400 million in the second tranche of a Series C round led by Baillie Gifford, Yunfeng Capital, CPE, and electric vehicle battery...
China AI chip player Enflame raises $279m Series C
Enflame Technology, a Chinese artificial intelligence (AI) chip designer, has raised a RMB1.8 billion ($279 million) Series C round led by CPE, China Capital Investment Group, and Primavera Capital.
DCP, CPE make $300m China data center play
DCP Capital Partners and CPE – formerly CITIC Private Equity – have led a $300 million investment in Hotwon Group, a Chinese cloud computing infrastructure services provider.
JD Health targets largest Chinese PE-backed IPO in two years
JD Health, a Chinese online-to-offline healthcare business that raised around $1.9 billion from private investors after it spun out from JD.com, is looking to raise HK$26.9 billion ($3.48 billion) in its Hong Kong IPO.
China's JW Therapeutics trades up after $300m Hong Kong IPO
JW Therapeutics, a private equity-backed Chinese drug developer specializing in CAR T-cell therapies that engineer immune cells to fight cancers, has raised HK$2.33 billion ($300 million) through a Hong Kong IPO.
PE-backed JD Health files for Hong Kong IPO
JD Health, the healthcare unit of Chinese e-commerce giant JD.com, has filed for Hong Kong IPO. The company’s backers include Hillhouse Capital, CPE, CICC Capital, and Baring Private Equity Asia.
China medical device player Hanyu Medical secures $72m
China-based medical devices manufacturer Hanyu Medical has raised a RMB500 million ($72 million) Series D co-led by HighLight Capital, CPE (formerly known as CITIC Private Equity), and Yingke Private Equity.
CPE, GDS team up on China data center project
CPE - formerly CITIC Private Equity - and GDS Holdings have jointly acquired a greenfield data center project in China that will represent a RMB2.6 billion ($371 million) investment upon completion.
CPE, Mirae lead $100m Series B for China's JW Therapeutics
JW Therapeutics, a China cancer treatment specialist established by Bristol Myers Squibb-owned Juno Therapeutics and China’s WuXi AppTec, has received $100 million in Series B funding.